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Abstract: Rapid diagnostics for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are
paramount for reducing the spread of the current pandemic. During additional seasonal epidemics with
influenza A/B and respiratory syncytial virus (RSV), the clinical signs and symptoms cannot be dis-
tinguished easily from SARS-CoV-2. Therefore, a new assay combining four targets in the form of the
new Xpert Xpress SARS-CoV-2/Flu/RSV assay was evaluated. The assay was compared to the Xpert
Xpress SARS-CoV-2, Xpert Xpress Flu/RSV, Seegene Flu/RSV, influenza A/B r-gene® and RSV/hMPV
r-gene®. A total of 295 nasopharyngeal and throat swabs were tested at four institutes throughout Eu-
rope including 72 samples positive for SARS-CoV-2, 65 for influenza A, 47 for influenza B, and 77 for
RSV. The sensitivity of the new assay was above 95% for all targets, with the highest for SARS-CoV-2
(97.2%). The overall correlation of SARS-CoV-2 Ct values between Xpert Xpress SARS-CoV-2 assay
and Xpert Xpress SARS-CoV-2/Flu/RSV assay was high. The agreement between Ct values above 30
showed the multiplex giving higher Ct values for SARS-CoV-2 on average than the singleplex assay. In
conclusion, the new assay is a rapid and reliable alternative with less hands-on time for the detection of
not one, but four upper respiratory tract pathogens that may circulate at the same time.
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Rapid diagnostics for severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐
2) are paramount for reducing the spread of the current pandemic. During addi-
tional seasonal epidemics with influenza A/B and respiratory syncytial virus (RSV),
the clinical signs and symptoms cannot be distinguished easily from SARS‐CoV‐2.
Therefore, a new assay combining four targets in the form of the new Xpert Xpress
SARS‐CoV‐2/Flu/RSV assay was evaluated. The assay was compared to the Xpert
Xpress SARS‐CoV‐2, Xpert Xpress Flu/RSV, Seegene Flu/RSV, influenza A/B
r‐gene® and RSV/hMPV r‐gene®. A total of 295 nasopharyngeal and throat swabs
were tested at four institutes throughout Europe including 72 samples positive for
SARS‐CoV‐2, 65 for influenza A, 47 for influenza B, and 77 for RSV. The sensitivity
of the new assay was above 95% for all targets, with the highest for SARS‐CoV‐2
(97.2%). The overall correlation of SARS‐CoV‐2 Ct values between Xpert Xpress
SARS‐CoV‐2 assay and Xpert Xpress SARS‐CoV‐2/Flu/RSV assay was high. The
agreement between Ct values above 30 showed the multiplex giving higher Ct
values for SARS‐CoV‐2 on average than the singleplex assay. In conclusion, the new
assay is a rapid and reliable alternative with less hands‐on time for the detection of
not one, but four upper respiratory tract pathogens that may circulate at the
same time.
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1 | INTRODUCTION
A year into the current severe acute respiratory syndrome coronavirus 2
(SARS‐CoV‐2) pandemic, the number of cases remain high and with new
mutations resulting in increased infectiousness and transmission, this will
most likely remain of concern at least until a significant percentage of the
population is vaccinated or naturally immunized.1,2 A fast and accurate
SARS‐CoV‐2 diagnostic remains important to identify infected persons,
reduce transmission and gather data for surveillance purposes. A short-
age of consumables, protective materials, and polumerase chain reaction
(PCR) platform capacity is thus seen. During winter, other respiratory
viruses such as influenza A/B and respiratory syncytial virus (RSV), which
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are usually epidemic in Europe between November and April, may co-
incide with SARS‐CoV‐2.3,4 However, recent data from Australia show
that those seasonal epidemics have been reduced during the SARS‐CoV‐
2 pandemic, possibly as a result of isolation, restricted travel, and social
distancing.5 These respiratory viruses often show initial similar symptoms
and cannot be differentiated on clinical presentation alone. However,
they do require different isolation regimens, depending on the patient
category, such as children, elderly, and the immunocompromised and the
course of the diseases evolve differently according to each virus.6–9
Additionally, treatment options differ and surveillance of individual pa-
thogens is relevant for public health decision making.10,11 To distinguish
between four of the most common and clinically relevant seasonal airway
pathogens and to be able to identify coinfections rapidly, a multiplex
PCR, the Xpert Xpress SARS‐CoV‐2/Flu/RSV (multiplex) has been made
available.12,13 The aim of this study was to evaluate this new multiplex
PCR assay in a European multicenter setting.
2 | MATERIALS AND METHODS
2.1 | Study sites and samples selection
Samples from archived collections were selected at four institutes
throughout Europe. The Radboud University Medical Center in Nij-
megen the Netherlands, the Medical University of Graz in Austria,
the Institute of Medical Virology, the University of Zurich/University
Hospital Zurich in Switzerland, and the University Hospital of Re-
nnes, in France. Each institute selected samples positive for
SARS‐CoV‐2, influenza‐A, influenza B, and RSV. Those samples have
previously been tested on a range of different platforms. A total of
295 clinical samples were included. The range of Ct values is shown
in Table 1.
2.2 | Reference method
2.2.1 | Radboud University Medical Center
Samples consisted of nasopharyneal and/or throat swabs in UTM or
GLY medium (Table 1) and stored at −80°C. SARS‐Cov‐2 was tested
using Xpert Xpress SARS‐CoV‐2 (singleplex) and Xpert Xpress Flu/
RSV was used for the influenza A, B, and RSV positive samples. All
samples underwent one freeze‐thaw cycle before use in the valida-
tion of the SARS‐CoV‐2/Flu/RSV cartridge. Three samples included
were co‐infections. Two of the samples selected as influenza A po-
sitive were also RSV positive. One influenza A sample was also SARS‐
CoV‐2 positive.
2.2.2 | Medical University of Graz
Left‐over routine samples that had been obtained by a deep or-
opharyngeal swab with the Copan UTM™ (Copan) collection system
and had been stored at −80°C were used for this study. All SARS‐
CoV‐2 diagnostics were performed using the Xpress Xpress SARS‐
CoV‐2 cartridge. Influenza A and B was tested using the Influenza A/
B R‐GENE® (bioMerieux SA) assay, RSV using the RSV/hMPV
R‐GENE® (bioMerieux) assay. After extraction on the NicliSENS®
EMAG® (bioMerieux) platform using the specific B protocol, ampli-
fication and detection were performed on the LC 480 II (Roche Di-
agnostics International Ltd.). Additionally, the CELL Control
R‐GENE® (bioMerieux) kit was used for each sample. This assay in-
cludes an amplification premix detecting the human hypoxanthine
phosphor‐ribosyl transferase 1 gene and thus checking for the pre-
sence of human cells in the sample. Four samples included were
coinfections, three were influenza A with RSV and one sample was
influenza B with RSV.
2.2.3 | Institute of Medical Virology, University of
Zurich/University Hospital Zurich
Samples of nasopharyngeal and throat swabs tested for SARS‐CoV‐2
were collected in an in‐house virus transport medium (HEPES,
DMEM, FCS, antibiotics) and stored before use at −80°C, samples
tested for influenza A/B and RSV were stored at −20°C. All samples
underwent one freeze‐thaw cycle before use in the validation of the
SARS‐CoV‐2/Flu/RSV cartridge. All samples, SARS‐CoV‐2, influenza
A/B, and RSV were tested using Xpert Xpress SARS‐CoV‐2 or Xpert
Xpress Flu/RSV. Three out of 10 RSV positive samples were tested
previously using an in‐house PCR.14 Samples with coinfections were
not included.
2.2.4 | Rennes University Hospital
All samples were nasopharyngeal swabs collected in either TranSwab
or eSwab medium and stored at −80°C until use. SARS‐Cov‐2 was
tested using Xpert Xpress SARS‐CoV‐2 (singleplex). influenza A/B
and RSV were tested using Seegene Allplex respiratory panel 1
(Eurobio) as recommended by the manufacturer. Seven included
samples had coinfections as determined using the Seegene techni-
que. Five samples were both influenza A and RSV positive, one
sample was influenza B and RSV positive. One sample was influenza
A and B positive.
2.3 | Xpert Xpress SARS‐CoV‐2/Flu/RSV
The Xpert SARS‐CoV‐2/Flu/RSV assay was performed at each par-
ticipating institute according to the manufacturer's protocol and
using research use only cartridges. Briefly, 300 µl of the sample was
added to the cartridge, with a run time of 36min on a GeneXpert
platform. The cartridge performs sample preparation, RNA isolation,
reverse transcription, and PCR in one single test, without additional
hands‐on time. All discrepant results were repeated if sufficient
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sample material was available. Targets for SARS‐CoV‐2, influenza A/
B, and RSV are similar to the individual cartridges (singleplex SARS‐
CoV‐2 and the Flu/RSV). The multiplex assay reports four separate
Ct values for SARS‐CoV‐2, Flu A, Flu B, and RSV. The main difference
with Xpert SARS‐CoV‐2 is that the multiplex assay reports 1 Ct value
for both N2 and E targets (mix) and the singleplex assay reports 2 Ct
values (E and N2).
3 | STATISTICAL ANALYSIS
Positive (PPA) and negative (NPA) percentage agreement of Xpert
Xpress SARS‐CoV‐2/Flu/RSV was calculated using cross tables and
analysed using IBM SPSS Statistics, version 25.0. To evaluate the
agreement between tests, linear regression analysis with Passing‐
Bablok fit, a Shapiro–Wilk test for normality of the difference, and a
Bland–Altman plot were calculated using Analyse‐it Software, Ltd.
and SPSS (version 25; IBM Corporation). For Xpert Xpress SARS‐
CoV‐2 the average of E‐ and N2‐gene Ct values were calculated and
compared to the Ct values of the Xpert Xpress SARS‐CoV‐2/Flu/RSV.
4 | RESULTS
For all 121 SARS‐CoV‐2 positive samples tested with the new Xpert
Xpress SARS‐CoV‐2/Flu/RSV, a PPA of 97.2% and NPA of 100% was
observed compared to the reference assay performed at each institute
(Table 2). Two discrepant results were found; both samples tested
TABLE 2 Crosstables comparing Xpert Xpress SARS‐CoV‐2/Flu/RSV to the local method for SARS‐COV‐2 (i), influenza A (ii), influenza B
(iii), and RSV(iv) detection
Note: The green/orange background indicate discrepancies in the agreement between tests.
Abbreviations: NPA, negative percentage agreement; PPA, positive percentage agreement; RSV, respiratory syncytial virus; SARS‐CoV‐2, severe acute
respiratory syndrome coronavirus 2.
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positive with the reference method (Xpert Xpress SARS‐CoV‐2) but
negative with the multiplex assay. Upon retesting, one sample tested
negative with both assays (Table 3). The other sample showed Ct
values of 44.1 (E‐gene) and 42.9 (N2‐gene) with the singleplex assay.
Agreement of SARS‐CoV‐2 Ct values for Xpert Xpress SARS‐CoV‐
2 and Xpert Xpress SARS‐CoV‐2/Flu/RSV are shown in Figure 1. The
correlation between both tests was high (R2 = 0.89). Normal distribu-
tion of the differences was confirmed using the Shapiro–Wilks test to
TABLE 3 Samples (N = 11 out of 295) with discrepancies between Xpert Xpress SARS‐CoV‐2/Flu/RSV and comparator method
Note: Depicted for each target. Ct values of comparator method reported. The green/orange background indicate the details on individual samples showing
discrepancies between tests. *One SARS‐CoV‐2 sample was detected using the in‐house PCR and Xpert Xpress SARS‐CoV‐2 as was done for all other samples,
performed using COBAS 4800 with RT‐PCR described by Corman et al.15
Abbreviations: RSV, respiratory syncytial virus; RT‐PCR, reverse‐transcription polymerase chain reaction; SARS‐CoV‐2, severe acute respiratory
syndrome coronavirus 2.
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reliably construct the Bland–Altman plot. The plot depicted in zur2
showed a mean difference of 0.67 (95% CI: 0.0330–1.3133). For Ct
values above 30, the multiplex assay revealed higher Ct values com-
pared to the singleplex assay, whereas Ct values below 30 showed an
equal distribution (Figure 2).
For the other targets, the results are presented in Table 2. The
PPA for influenza A was 95.3%, for influenza B 95.6%, and for RSV
96.1%. Discrepant results were found in samples with high Ct values
(Table 3).
Fourteen samples showed co‐infections (eight influenza A plus
RSV, one influenza A plus SARS‐CoV‐2, four influenza B plus RSV,
and one influenza A plus B). Discrepant results were found in two
samples, both with very high Ct values (Table 3).
The limit of detection for Influenza A/B R‐GENE®, RSV/hMPV R‐
Gene, Seegene FluA/B/RSV is unavailable for these platforms.
5 | DISCUSSION
Early and rapid detection of SARS‐CoV‐2 remains vital to reduce the
current pandemic and optimize patient care. The Xpert Xpress
SARS‐CoV‐2 test has been available since March 2020. In previous
seasons, the Xpert Xpress Flu/RSV had been successfully used to
rapidly identify influenza and RSV in patients with respiratory
infections.13,16–18
For seasons with high influenza and RSV incidence coinciding
with the SARS‐CoV‐2 pandemic, the combined SARS‐CoV‐2/Flu/
RSV cartridge was developed. Overall, we found the PPA to be
above 95% for all tested targets, with the highest percentage for
SARS‐CoV‐2 (97.2%). The correlation between testing was found to
be high, which is to be expected when using two near‐identical
platforms with similar targets. However, the Bland–Altman plot
suggested that samples with Ct values above 30 show higher levels
in the multiplex compared to the singleplex assay, and this is not
equally distributed compared to samples below Ct 30. As the
number of samples at this higher Ct value is relatively low, a greater
sample size would be needed to identify if this is a common
occurrence.
Two samples were discordant for detection of SARS‐CoV‐2 be-
tween the singleplex and multiplex assays. One of the samples was
negative on retesting in the singleplex assay. This could either mean
that freeze‐thawing steps degraded the sample although this would
be relatively surprising as an initial Ct value of 33 is relatively low.
Alternatively, misclassification or sample mix‐up on initial testing
before selection of the sample could be the cause. The other dis-
cordant case occurred in a sample with a low viral load, which could
be near the limit of detection of the Xpert assay. This finding was
similar for samples positive for influenza A, B, and RSV by Xpert Flu/
RSV but negative by Xpert SARS‐CoV‐2/Flu/RSV. These discordant
cases could be caused by several freeze‐thaw steps as these samples
were not retested using the reference method at the same time as
testing with the multiplex assay.
In this study, throat and oropharyngeal swabs were used which
are not part of the claim for the Xpert assay. However, these sample
types are widely used in the field and are, in some countries, part of
national guidelines, which is why it is important to assess the per-
formance of the assay in this setting. Additionally, several types of
transport medium were used for collection of samples. These were
UTM/GLY medium, Copan UTM, and TranSwab or eSwab (Table 1).
Validation of transport medium was not performed in the current
assay however all transport media has previously been validated for
its use on the GeneXpert platform at the individual sites, where it has
been used in different cartridges or on other reference platforms
(Table 1) without reduction of sensitivity.
Overall, the results obtained from the new SARS‐CoV‐2/Flu/
RSV cartridge show good agreement with results obtained from
previous testing. The faster turn‐around time of only half an hour
is of major significance for fast and accurate treatment as well as
for public health decisionmaking during the current SARS‐CoV‐2
pandemic.
F IGURE 1 Linear regression of Ct values for SARS‐CoV‐2
singleplex and SARS‐CoV‐2/Flu/RSV multiplex. Slope of 0.9554 and
correlation (r) of 0.943. RSV, respiratory syncytial virus; SARS‐CoV‐
2, severe acute respiratory syndrome coronavirus 2
F IGURE 2 Bland–Altman plot with the difference in Ct value
(multiplex–singleplex) on the Y‐axis and average of single‐ and
multiplex on the X‐axis
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